Alerts

Further examples of counterfeit Ozempic-labelled products have been detected and stopped at the Australian border.

Takeda Pharmaceuticals Australia has issued a product alert for Vyvanse capsules due to minor packaging errors. The medication is safe to use as prescribed.

Magnum XXL capsules pose a serious risk to your health and should not be taken.

More prominent warnings are being added to the Product Information and Consumer Medicine Information for all oral and injectable (systemic) fluoroquinolones to strengthen existing warnings about serious side effects.

Extra safety information is being added to all montelukast products to highlight the existing warnings about serious behaviour and mood-related changes

Pharmacists can use a Serious Scarcity Substitution Instrument (SSSI) to dispense Protaphane Penfill human insulin in the place of a Protaphane InnoLet cartridge.

A shortage of Bicillin L-A 1.2 million unit prefilled syringes is anticipated from 20 December 2024 to 10 January 2025. A PBS-listed substitute product is available.

Pharmacists may dispense alternative brands or strengths without a new prescription.

The oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be given to children under 6 years of age.

Metalyse is now available for use in all clinical settings.

We have made a new Serious Scarcity Substitution Instrument to help manage the shortage and upcoming discontinuation of Ryzodeg 70/30 FlexTouch insulin.

The new KwikPen presentation of Mounjaro is now available but supply of all strengths of Mounjaro vials remains limited.

We have been advised that Novo Nordisk will gradually discontinue some of its earlier generation insulin products over the next 2 years.

Shortage resolved

We have become aware of an increasing number of cases of liver injury reported in scientific literature, by consumers who had taken products containing Garcinia gummi-gutta.

Pharmaceutical company Novo Nordisk has advised us that a new brand of semaglutide approved for chronic weight management, Wegovy, will be available in Australia from early August 2024.

Medicine shortage alert

Robust Extreme capsules pose a serious risk to your health and should not be taken.

Shortage resolved

Due to Oxynorm being reinstated in Australia and Ordine shortage extension

Current shortage of Vyvanse 20 mg and anticipated shortage of Vyvanse 60mg capsules.

Fluoxetine substitution instrument has been extended.

extension of SSSI

Pharmacists can now substitute one Orencia 125 mg product for the other

Find out about the shortage of Orencia (abatacept) 125 mg/mL ClickJect autoinjector and prefilled syringe for subcutaneous injection.